ATLANTA--(BUSINESS WIRE)--AACC – Aalto Bio Reagents, the largest provider of raw materials and controls to the in-vitro diagnostics industry and to research laboratories, today announced the availability of the first full range of Hepatitis B Virus (HBV) human plasma intended for production of positive controls and QC in the industry. There are over 4 million acute clinical cases of HBV, and about 25% of carriers, 1 million people a year, die from chronic active hepatitis, cirrhosis or primary liver cancer.
Transmission of HBV is via person to person through blood and other bodily fluids and infection can be classed as acute or chronic depending on the longevity of the virus. Acute infection lasts <6 months whereas chronic infection lasts >6 months and can potentially lead to cirrhosis and hepatocellular carcinoma (a type of liver cancer).
Aalto Bio Reagents is now offering the following HBV material:
- Anti-HBs positive (negative for HBsAg, anti-HIV-1/2 and anti-HCV)
- Anti-HBc (IgM and total) positive*
- Anti-HBe positive*
- HBsAg (ad, ay) positive*
- HBeAg positive*
*This material is negative for anti-HIV-1/2 and anti-HCV however is potentially infectious due to the presence of HBsAg.
“Our industry has an unrelenting requirement for access to the most scientifically proven raw materials, a broader range of flexible controls and faster diagnostics. At Aalto Bio Reagents we are continuously expanding our product portfolio to meet this need. By bringing a comprehensive suite of HBV raw materials as well as recent raw material development for a range of recombinant Chikungunya Virus antigens and partially purified cell culture derived IgE we continue to enable our clients to bring superior best-in-class diagnostic products to market faster.” said Philip Noone, CEO, Aalto Bio Reagents.
About Aalto Bio Reagents
Founded in 1978, Aalto Bio Reagents is the leading provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; disease state plasma and molecular controls for in-vitro diagnostic application.
Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit www.aaltobioreagents.com